Sermorelin Geriatric (65+) Monitoring: A Complete Clinical Guide

Why Geriatric Patients Need a Different Monitoring Framework

Older adults are not simply older versions of younger patients. By age 65, endogenous growth hormone (GH) secretion has declined by roughly 14% per decade from peak levels in early adulthood, a phenomenon sometimes called the somatopause [1]. Sermorelin acts by binding pituitary GHRH receptors to stimulate pulsatile GH release, but the aging pituitary has fewer somatotroph cells and a blunted response to GHRH stimulation [2]. This means the same dose that produces a strong IGF-1 rise in a 40-year-old may produce a smaller, slower response in a 70-year-old.

Physiologic changes compound this. Renal clearance of peptides decreases with age: the average eGFR at age 75 is approximately 60 to 65 mL/min/1.73 m², compared to 90+ mL/min/1.73 m² at age 30 [3]. Slower peptide clearance means sermorelin and its metabolites accumulate at standard doses, increasing exposure and adverse-event risk. Body composition also shifts toward higher fat mass and lower lean mass, altering the volume of distribution for water-soluble peptides [4].

Finally, polypharmacy is the rule in geriatric patients. The average American over 65 takes five or more prescription medications [5]. Several of those drug classes, including insulin, oral hypoglycemics, and glucocorticoids, interact directly with the GH-IGF-1 axis and must be accounted for when interpreting sermorelin monitoring results.

Baseline Evaluation Before Starting Sermorelin in Patients 65 and Older

Every geriatric patient should complete a structured baseline workup before the first sermorelin dose. The evaluation has three goals: confirm that GH deficiency is present and clinically significant, rule out contraindications, and establish a documented safety baseline for future monitoring comparisons.

Laboratory panel at baseline:

Serum IGF-1 with an age- and sex-adjusted reference range. The Endocrine Society's 2011 Clinical Practice Guideline for GH Deficiency in Adults states that IGF-1 below the age-matched reference range supports the diagnosis of adult GH deficiency, but should be interpreted alongside clinical findings rather than in isolation [6]. A fasting glucose and HbA1c are essential because GH is counter-regulatory to insulin; any pre-existing impaired fasting glucose or HbA1c of 5.7 to 6.4% raises the risk of hyperglycemia on therapy. A comprehensive metabolic panel (CMP) documents baseline renal and hepatic function. A fasting lipid panel is useful because GH deficiency is associated with an unfavorable lipid profile and treatment response can be tracked [7]. A CBC screens for any underlying hematologic condition.

Clinical assessment at baseline:

Functional status and fall risk must be documented before starting sermorelin. The CDC's STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm provides a standardized, validated framework for fall-risk stratification in community-dwelling adults over 65 [8]. Fluid retention, carpal tunnel symptoms, and arthralgias are the most common adverse effects of GH-axis stimulation; documenting their absence at baseline prevents misattribution later [9]. Blood pressure and weight should be recorded because GH affects sodium retention and fluid balance [10].

Thyroid function (TSH, free T4) should be checked: untreated hypothyroidism blunts the IGF-1 response to sermorelin, and GH therapy can unmask subclinical hypothyroidism by increasing peripheral conversion of T4 to T3 [6].

IGF-1 Targets and Dose Titration in Geriatric Patients

The single most important number to track is serum IGF-1. In geriatric sermorelin monitoring, the target is the lower-to-middle of the age- and sex-adjusted reference range, not the upper quartile.

This target differs from what some clinicians use in younger adults. The Endocrine Society guideline specifies that GH replacement should be titrated to achieve an IGF-1 in the normal range for age and sex, with the lowest effective dose preferred [6]. Keeping IGF-1 in the lower half of the normal range for a 65-to-75-year-old minimizes the risk of adverse effects (fluid retention, hyperglycemia, worsening insulin resistance) while still providing the lean mass and bone benefits associated with GH axis normalization [11].

Typical IGF-1 reference ranges for adults aged 65, 74 are approximately 60 to 200 ng/mL for men and 45 to 190 ng/mL for women, though laboratory-specific ranges vary. Clinicians should use the reference intervals provided by the specific assay laboratory and document which assay platform was used at each draw to ensure longitudinal comparability [12].

Titration schedule:

Start at 100 to 150 mcg subcutaneously at bedtime. Recheck IGF-1 at 6 weeks. If IGF-1 remains below the age-adjusted reference range and no adverse effects are present, increase to 200 mcg. Recheck at 12 weeks. If IGF-1 is within the target range, maintain the dose and recheck every 3 months for the first year, then every 6 months thereafter if stable. If IGF-1 exceeds the upper limit of the age-adjusted normal range at any point, reduce the dose by 25 to 50 mcg and recheck in 4 weeks [6].

Never titrate sermorelin to symptoms alone in geriatric patients. Subjective improvement in energy or sleep quality can precede measurable IGF-1 changes and may reflect placebo response or spontaneous variation rather than pharmacologic effect [13].

Renal Function Monitoring and Dose Adjustments

Sermorelin is a 29-amino-acid peptide cleared primarily by renal peptidases and glomerular filtration. No large pharmacokinetic study in elderly patients with chronic kidney disease (CKD) has been published in the peer-reviewed literature, but general principles of peptide pharmacokinetics support caution when eGFR falls below 45 mL/min/1.73 m² [3].

CKD stage 3b (eGFR 30 to 44 mL/min/1.73 m²) or worse is present in approximately 11% of adults aged 65 and older in the United States [14]. For these patients, a conservative approach is warranted. A 25 to 50% dose reduction from the starting dose of 100 to 150 mcg is reasonable when eGFR falls below 45 mL/min/1.73 m², with more frequent IGF-1 monitoring (every 4 weeks during titration) to detect accumulation. Sermorelin should generally be avoided in patients with eGFR <30 mL/min/1.73 m² or those on dialysis given the absence of safety data in that population.

Renal function should be checked at baseline, at 3 months, and at least annually thereafter. An acute decline in eGFR of more than 20% from baseline should prompt temporary dose reduction and nephrology consultation [14].

Glucose Metabolism: Monitoring and Managing Hyperglycemia Risk

GH is a counter-regulatory hormone. It reduces peripheral insulin sensitivity through post-receptor signaling mechanisms, and this effect persists when GH is raised via sermorelin [15]. In healthy young adults, this is generally offset by compensatory insulin secretion. In geriatric patients, who have higher rates of pre-diabetes and type 2 diabetes and whose beta-cell reserve may be reduced, the risk of clinically significant hyperglycemia is meaningfully higher.

The FDA has noted that GH and GH-stimulating compounds can reduce insulin sensitivity, and this is reflected in product labeling for GH therapies approved for adult GH deficiency [16]. Fasting glucose should be checked at baseline, at 6 weeks, at 3 months, and every 6 months thereafter. HbA1c should be checked at baseline and every 6 months. If fasting glucose rises above 100 mg/dL from a normal baseline, or if HbA1c rises by more than 0.3% from baseline, re-evaluate the benefit-to-risk ratio and consider dose reduction [15].

Patients already on insulin or oral hypoglycemics need closer monitoring. The dose of their diabetes medication may need upward adjustment, or sermorelin may need to be reduced. Coordinate care with the patient's primary care provider or endocrinologist when adjusting concurrent diabetes medications [6].

Fall and Fracture Risk: The Overlooked Sermorelin Monitoring Domain

Falls are the leading cause of injury-related death in adults over 65 in the United States, with approximately 36 million falls occurring annually in this age group [17]. Sermorelin's effect on this risk is bidirectional. On one hand, GH and IGF-1 support muscle protein synthesis and bone mineral density, potentially reducing sarcopenia and osteoporosis over time [11]. On the other hand, fluid retention and peripheral edema, adverse effects seen with GH-axis stimulation, can impair proprioception and gait stability in older adults [9].

Sermorelin monitoring in geriatric patients must therefore include systematic fall-risk screening at baseline and every 6 months. The CDC's STEADI toolkit, freely available online, provides the Timed Up-and-Go (TUG) test, the 30-Second Chair Stand, and the 4-Stage Balance Test as validated physical performance measures for this purpose [8]. A TUG time of 12 seconds or more is associated with increased fall risk and should trigger a formal occupational therapy or physical therapy referral before or during sermorelin therapy [8].

Bone mineral density (DEXA scan) at baseline is recommended for all geriatric sermorelin patients, given the high background prevalence of osteopenia and osteoporosis in this age group. The National Osteoporosis Foundation recommends DEXA for all women over 65 and men over 70, and earlier if clinical risk factors are present [18]. Serial DEXA at 1 to 2 year intervals can document whether sermorelin therapy is contributing to bone density preservation.

If new edema, worsening gait instability, or a fall occurs during therapy, sermorelin should be temporarily held and the patient evaluated clinically before resuming at a reduced dose.

Drug-Drug Interactions in Geriatric Sermorelin Patients

The average geriatric patient on sermorelin is likely taking at least one drug that interacts with the GH-IGF-1 axis. Key interactions to monitor systematically follow below.

Glucocorticoids. Systemic corticosteroids suppress pituitary GHRH receptor sensitivity and reduce IGF-1 production at the liver. A patient on chronic prednisone 5 mg/day for rheumatoid arthritis may show little or no IGF-1 response to sermorelin [19]. The presence of glucocorticoid therapy should be documented, and clinicians should counsel patients that response may be attenuated.

Thyroid hormone. GH secretion and IGF-1 production both require adequate thyroid hormone. Untreated or undertreated hypothyroidism impairs the IGF-1 response to sermorelin. Conversely, initiating sermorelin may worsen subclinical hypothyroidism, because GH increases peripheral T4-to-T3 conversion and can suppress TSH [6]. Check TSH at 3 months after sermorelin initiation if not already being monitored.

Insulin and oral hypoglycemics. As noted above, GH reduces insulin sensitivity. Patients on sulfonylureas face a particular risk of relative hypoglycemia during the first weeks of sermorelin, as endogenous GH stimulation may temporarily increase free fatty acid availability and shift energy substrate use, before stabilizing at a higher insulin-resistance set point [15]. Monitor fasting glucose weekly for the first 4 weeks in patients on sulfonylureas.

Androgens and estrogens. Sex hormones modulate GH pulsatility and IGF-1 production. Testosterone replacement in men increases GH pulse amplitude; estrogen at supraphysiologic doses (oral estrogen) blunts hepatic IGF-1 production. Geriatric patients on hormone therapy should have their IGF-1 interpreted in the context of concurrent sex-hormone status [20].

Monitoring Cognitive and Quality-of-Life Outcomes

Evidence for sermorelin specifically in geriatric patients with cognitive symptoms is limited. The primary pediatric trial by Walker et al. (Pediatrics 1990, N=121) documented growth velocity in children with GH deficiency but does not speak to geriatric quality-of-life or cognitive outcomes [21]. Adult GH deficiency trials with recombinant GH (rhGH) show modest improvements in quality of life, body composition, and bone density, with less clear effects on cognition [22].

Clinicians should use a validated instrument to track self-reported outcomes. The QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) is the most widely cited patient-reported outcome tool in adult GH deficiency research [22]. Administer it at baseline, at 3 months, and at 12 months. A failure to show any improvement in QoL-AGHDA score after 6 months of sermorelin therapy, in the absence of IGF-1 response, is a deprescribing signal.

Objective cognitive testing (e.g., Montreal Cognitive Assessment, MoCA) at baseline and annually provides a safety screen: if cognition declines during sermorelin therapy, the therapy should be reviewed as a possible contributing factor, even though causation is not established [23].

Deprescribing Criteria for Sermorelin in Geriatric Patients

Deprescribing, the planned and supervised reduction or cessation of medications, is a cornerstone of geriatric pharmacology [24]. Sermorelin is no exception. Clear stopping criteria should be established in the initial prescribing conversation and documented in the medical record.

Consider discontinuation if any of the following occur: IGF-1 remains below the age-adjusted reference range after 6 months at the maximum tolerated dose; fasting glucose rises above 126 mg/dL on two separate measurements; a new fall or fragility fracture occurs without an alternative explanation; eGFR declines to <30 mL/min/1.73 m²; the patient develops a new malignancy (GH-axis stimulation is contraindicated in active malignancy) [16]; or the patient or caregiver expresses a preference to discontinue after an informed discussion of benefits and burdens.

When discontinuing, there is no established taper protocol for sermorelin. Unlike glucocorticoids or opioids, sermorelin does not produce physiologic dependence. Abrupt cessation is clinically reasonable. IGF-1 typically returns to pre-treatment baseline within 4 to 6 weeks of stopping sermorelin, based on the known half-life of sermorelin (approximately 11 to 12 minutes plasma half-life, with downstream IGF-1 effects lasting days to weeks) [25].

Compounding Pharmacy Oversight and Documentation Requirements

Sermorelin acetate is not an FDA-approved drug product in the United States as of mid-2025. It is available only through 503A compounding pharmacies operating under state pharmacy board oversight and section 503A of the Federal Food, Drug, and Cosmetic Act [16]. This has direct implications for geriatric monitoring.

Prescribers must document a specific patient-individualized prescription. Batch manufacturing (503B outsourcing facility production) is not permitted for sermorelin under current FDA policy [16]. Each prescription must specify the dose, concentration, volume, and route; standard formulations are typically sermorelin acetate 5 mg/mL or 9 mg/mL reconstituted in bacteriostatic water for subcutaneous injection.

For geriatric patients, the reconstitution and injection technique deserve attention. Reduced manual dexterity, visual impairment, and cognitive changes can compromise injection accuracy. A nursing or pharmacy-led injection training session at initiation, with a caregiver present if appropriate, reduces dosing errors. Document training in the medical record.

Lot numbers and compounding pharmacy accreditation status (PCAB accreditation through the Pharmacy Compounding Accreditation Board is voluntary but an indicator of quality) should be recorded at each prescription fill to support pharmacovigilance.

Summary Monitoring Schedule

The table below consolidates the recommended monitoring timeline for sermorelin in patients aged 65 and older.

| Assessment | Baseline | 6 Weeks | 3 Months | 6 Months | 12 Months | Annually | |---|---|---|---|---|---|---| | Serum IGF-1 | X | X | X | X | X | X | | Fasting glucose | X | X | X | X | X | X | | HbA1c | X | | X | X | X | X | | CMP / eGFR | X | | X | | X | X | | Fasting lipids | X | | | X | X | X | | TSH / free T4 | X | | X | | X | X | | CBC | X | | | | X | X | | Fall-risk screening (STEADI) | X | | | X | | X | | DEXA scan | X | | | | X | Every 1, 2 yrs | | QoL-AGHDA | X | | X | | X | X | | Blood pressure / weight | X | X | X | X | X | X |